EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current Understandings of Myeloid Differentiation Inducers in Leukemia Therapy

Shinichiro Takahashi

Acta Haematologica · 2021 · 144 (4) · 380-388

DOI: 10.1159/000510980 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 20.11.2020. Verfasst von Shinichiro Takahashi. Beteiligte Einrichtung: Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, shintakahashi@tohoku-mpu.ac.jp. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Differentiation therapy using all-trans retinoic acid for acute promyelocytic leukemia (APL) is well established. Several attempts have been made to treat non-APL, AML patients by employing differentiation inducers, such as hypomethylating agents (HMAs), and low-dose cytarabine (Ara-C) (LDAC), with encouraging results. Other than HMAs and LDAC, various inducers of myeloid cell differentiation have been identified. This review describes and categorizes these inducers, which include glycosylation modifiers, epigenetic modifiers, vitamin derivatives, cytokines, and chemotherapeutic agents. Some of these inducers are currently being used in clinical trials. I highlight the potential applications of glycosylation modifiers and epigenetic modifiers, which are attracting increasing attention in their use as differentiation therapy against AML. Among the agents described in this review, epigenomic modifiers seem particularly promising, and particular attention should also be paid to glycosylation modifiers. These drugs may signal a new era for AML differentiation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCell DifferentiationEpigenomicsGlycosylationHumansLeukemia, Myeloid, AcuteMicroRNAsVitamins

Stichwörter der Autor:innen

Acute myeloid leukemiaDifferentiation therapyEpigenetic modifiersGlycosylation modifiers

Substanzen

Antineoplastic AgentsMicroRNAsVitamins

Autor:innen und Institutionen

  • Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, shintakahashi@tohoku-mpu.ac.jp.

Zitieren

APA

Takahashi, S. (2021). Current Understandings of Myeloid Differentiation Inducers in Leukemia Therapy. Acta Haematologica, 144(4), 380-388. https://doi.org/10.1159/000510980

Vancouver

Takahashi S. Current Understandings of Myeloid Differentiation Inducers in Leukemia Therapy. Acta Haematologica. 2021;144(4):380-388. doi:10.1159/000510980

BibTeX
@article{Takahashi2021,
  author = {Takahashi, Shinichiro},
  title = {Current Understandings of Myeloid Differentiation Inducers in Leukemia Therapy},
  journal = {Acta Haematologica},
  year = {2021},
  volume = {144},
  number = {4},
  pages = {380--388},
  doi = {10.1159/000510980}
}
Kostenlos starten →